Enliven Therapeutics Inc. has divulged Raf kinase inhibitors reported to be useful for the treatment of cancer. An exemplified compound (Ex 5 [isomer B] pg 130) inhibited ERK phosphorylation in human ...
A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This ...
Voronoi and Voronoi Bio Inc. have patented serine/threonine-protein kinase B-raf (BRAF), Raf kinase and Raf kinase B (V600E mutant) inhibitors reported to be useful for the treatment of cancer.
SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors ...
Forty percent to 60% of melanomas harbor a driver mutation in BRAF, most commonly V600E or K. This leads to constituent of activation of the MAPK pathway and increased activation of ERK, which drives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback